pulseline logo

Palliative Care to Trial Synthetic Psychedelic

How it works:

The trial will aim to give terminally ill patients a new perspective on their lives, during the final stage.

The administration will have to be guided by the hospital psychiatrist, under the guidelines of removing fear and depression from a dying patient.

Ask the expert:

Dr Margaret Ross, Clinical Psychologist at St Vincents Hospital.

“The studies would see patients given a single dose of psilocybin, which is so powerful it can unlock a section of a patient’s brains to give them an altered outlook on their situation approaching death.”

The details:

The trial has taken more than a year to gain approval by ethics committees as well as federal and state authorities

Related Stories


You have subscribed